The effecf of exercise with omega-3 and l-carnitine supplement consumption in women with type 2 diabetes

The effecf of 8-weeks combined exercise with omega-3 and l-carnitine supplement consumption on serum level visfatin in women with type 2 diabetes.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016070328751N1

Enrollment

Registered

2016-08-20

Start date

2016-07-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes type 2. Type 2 diabetes mellitus

Interventions

Intervention 1: exercise+l-carnitine. Intervention 2: omega3+l-carnitine. Intervention 3: exercise+pelasebo. Intervention 4: control. Intervention 5: exercise+omega3. Intervention 6: exercise+omega3+l

Treatment - Drugs

exercise+l-carnitine

omega3+l-carnitine

exercise+pelasebo

control

exercise+omega3

exercise+omega3+l-carnitine

Eligibility

Sex/Gender

Female

Age

40 Years to 64 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria Women with type 2 diabetes; according to the doctor at least three years past their diagnosis; blood sugar and blood pressure-lowering drugs blood glucose people only use blood fat. No change in blood glucose lowering drugs; blood fat and blood pressure in recent months, and should have blood pressure greater than 95/160 mm Hg. Exclusion criteria included insulin injections after the onset of the secondary complications of diabetes; such as protocol and having eye, kidney; diabetic foot ulcers and amputation and heart disease - cardiovascular; and inflammation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Visfatin. Timepoint: pretest? postest 8week. Method of measurement: serum.	—

Secondary

Measure	Time frame
FBS. Timepoint: Pretest?postest 8 week. Method of measurement: srum.;TG. Timepoint: pretest? postest 8 week. Method of measurement: Serum.;TC. Timepoint: pretest? postest 8 week. Method of measurement: Serum.;Ensoline. Timepoint: pretest? postest 8 week. Method of measurement: Serum.;LDL. Timepoint: pretest? postest 8 week. Method of measurement: Serum.;HDL. Timepoint: pretest? postest 8 week. Method of measurement: Serum.;Insulin resistance. Timepoint: pretest? postest 8 week. Method of measurement: formola.	—

Measure

Time frame

FBS. Timepoint: Pretest?postest 8 week. Method of measurement: srum.;TG. Timepoint: pretest? postest 8 week. Method of measurement: Serum.;TC. Timepoint: pretest? postest 8 week. Method of measurement: Serum.;Ensoline. Timepoint: pretest? postest 8 week. Method of measurement: Serum.;LDL. Timepoint: pretest? postest 8 week. Method of measurement: Serum.;HDL. Timepoint: pretest? postest 8 week. Method of measurement: Serum.;Insulin resistance. Timepoint: pretest? postest 8 week. Method of measurement: formola.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hassani Ali

Faculty Of Physical Education, Shahrood Univercity Of Technology

hassani_3@yahoo.com+98 23 3239 2205

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026